LBA02-06 PROSPECTIVE EVALUATION OF ¹⁸ F-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF ¹⁸ F-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES

You have accessJournal of UrologyLate-breaking Abstract II - Malignant1 Sep 2021LBA02-06 PROSPECTIVE EVALUATION OF 18F-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS UPTAKE POSSIBLE EXTRA-PELVIC OLIGOMETASTASES Hong Song, Judy Nguyen, Farshad Moradi, Carina Mari Aparici, Ben Franc, Guido Davidzon, and Andrei Iagaru SongHong Song More articles by this author , NguyenJudy Nguyen MoradiFarshad Moradi ApariciCarina Aparici FrancBen Franc DavidzonGuido Davidzon IagaruAndrei View All Author Informationhttps://doi.org/10.1097/JU.0000000000002149.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail INTRODUCTION AND OBJECTIVE: We prospectively evaluated a PET agent targeting prostate specific membrane antigen (PSMA), 18F-DCFPyL, in single center study for detecting recurrent lesions cancer patients with biochemical recurrence (BCR). METHODS: enrolled 223 men (49-91 years old, mean ± SD: 69.8±8.1) (PSA median 2.0 ng/mL, range 0.12 698.4) after primary definitive treatment prostatectomy (72%), radiotherapy (28%) or both (25%). The 18F-DCFPyL positive compatible were two independent readers. Patients possible extra-pelvic oligometastases (1-3 uptake) identified. maximum standardized uptake values (SUV max) these measured used categorize into high max ≥parotid gland SUV mean), moderate (parotid >SUV ≥liver mean) mild (liver ≥blood pool mean). RESULTS: had an overall positivity rate 84% (172 scans), which increased higher (PSA) levels (ng/mL): 62% <0.5), 77% (0.5 ≤PSA <1), 90% (1 <2), 92% (2 <5) 96% ≥5), respectively. In the cohort who underwent prostatectomy, shorter PSA doubling time (PSAdt) (93% PSAdt 0-3 months vs. 63% >12 months, p <0.01). Higher was also observed Gleason score (GS) (92% GS 8-10 vs 71% 72% 6-7, No difference post-radiation different GS. identified 62 total 109 oligometastases. Among them, there are 60 osseous (8 high, 16 36 uptake), 40 lymph nodes (9 13 18 9 other such as lung nodules (6 2 1 uptake). 27 out (44%) received locally targeted therapy (radiation surgery) without androgen deprivation therapy. CONCLUSIONS: holds great potential be “one-stop shop” diagnostic tool work-up BCR identify Source Funding: Progenics Pharmaceuticals © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1177-e1178 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...